News
AZ’s Fasenra hits the mark in phase IIIb asthma trial
AstraZeneca’s monoclonal antibody (mAb) significantly eliminated oral corticosteroid (OCS) use in OCS-dependent asthma patients with a broad range of blood eosinophils counts.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
AstraZeneca’s monoclonal antibody (mAb) significantly eliminated oral corticosteroid (OCS) use in OCS-dependent asthma patients with a broad range of blood eosinophils counts.